Recent Finacing
Recent Raise
Eiger Biopharmaceuticals is a clinical-stage biotech developing prenylation-inhibitor therapies for hepatitis D and C, advancing candidates such as EBP921 and EBP994 in clinical trials.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
